# US 2015/0031623 A1 · Thrombopoietin receptor ligands for neuroprotection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0031623 A1
- Document ID: US20150031623A1
- Status: Published application
- Kind: A1
- Application number: 14/348,147
- Filed: 2011-09-29
- Published: 2015-01-29
- Earliest claimed: 2011-09-29
- Assignees: MCW Research Foundation, Inc.
- Inventors: John E. Baker
- Web page: https://patentgrep.com/patent/US20150031623A1

## CPC

- C07K 16/26: against hormones {; against hormone releasing or inhibiting factors}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/4152: having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
- A61K 38/196: {Thrombopoietin}
- A61K 38/22: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35)
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides therapeutic modalities for the treatment of an ischemic event (e.g., stroke) that creates or embodies a risk of neurological damage in CNS sites by administration of a thrombopoietin receptor ligand.

## Claims

### Claim 1

A method comprising steps of:
administering to a subject who is suffering from or has recently suffered a an ischemic event that creates or embodies a risk of neurological damage in CNS sites, a composition comprising a thrombopoietin receptor ligand, which composition is formulated and contains an amount of thrombopoietin receptor ligand sufficient to achieve delivery of the thrombopoietin receptor ligand to the CNS.

### Claim 2 (depends on 1)

The method of claim 1 wherein the step of administering comprises administering at least one dose of the composition within a time window that is not more than 35 minutes of onset of symptoms of the ischemic event.

### Claim 3 (depends on 1)

The method of claim 1, wherein the step of administering comprises administering only one dose.

### Claim 4 (depends on 1)

The method of claim 1, wherein the step of administering comprises administering not more than one dose per day.

### Claim 5 (depends on 1)

The method of claim 1, wherein the step of administering comprises administering a plurality of doses.

### Claim 6 (depends on 5)

The method of claim 5, wherein all doses in the plurality are administered within the time window.

### Claim 7 (depends on 2)

The method of claim 2, wherein the step of administering comprises administering only one dose.

### Claim 8 (depends on 2)

The method of claim 2, wherein the step of administering comprises administering not more than one dose per day.

### Claim 9 (depends on 2)

The method of claim 2, wherein the step of administering comprises administering a plurality of doses.

### Claim 10 (depends on 9)

The method of claim 9, wherein all doses in the plurality are administered within the time window.
